BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,083 filers reported holding BAXTER INTL INC in Q3 2019. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $435,170 | -39.5% | 13,010 | -22.7% | 0.04% | -36.1% |
Q1 2024 | $719,756 | 0.0% | 16,840 | -9.5% | 0.06% | -9.0% |
Q4 2023 | $719,756 | +32.0% | 18,618 | +28.9% | 0.07% | +17.5% |
Q3 2023 | $545,218 | -35.0% | 14,447 | -21.5% | 0.06% | -38.0% |
Q2 2023 | $838,649 | +17.4% | 18,408 | +4.5% | 0.09% | +21.1% |
Q1 2023 | $714,229 | -20.9% | 17,609 | -0.6% | 0.08% | -26.2% |
Q4 2022 | $903,297 | -3.9% | 17,722 | +1.5% | 0.10% | -5.5% |
Q3 2022 | $940,000 | -24.8% | 17,459 | -10.3% | 0.11% | -16.2% |
Q2 2022 | $1,250,000 | -15.8% | 19,468 | +1.7% | 0.13% | -3.0% |
Q1 2022 | $1,485,000 | -19.7% | 19,151 | -11.1% | 0.13% | -3.6% |
Q4 2021 | $1,849,000 | +11.5% | 21,542 | +4.5% | 0.14% | +2.2% |
Q3 2021 | $1,658,000 | +21.4% | 20,609 | +21.5% | 0.14% | +19.3% |
Q2 2021 | $1,366,000 | -5.1% | 16,966 | -0.6% | 0.11% | -13.0% |
Q1 2021 | $1,440,000 | +5.2% | 17,070 | +0.1% | 0.13% | -3.0% |
Q4 2020 | $1,369,000 | -0.5% | 17,059 | -0.3% | 0.14% | -11.8% |
Q3 2020 | $1,376,000 | -17.9% | 17,116 | -12.1% | 0.15% | -23.1% |
Q2 2020 | $1,676,000 | +26.0% | 19,466 | +18.8% | 0.20% | +7.0% |
Q1 2020 | $1,330,000 | -52.0% | 16,381 | -50.5% | 0.19% | +27.4% |
Q4 2019 | $2,772,000 | +104.4% | 33,110 | +113.6% | 0.15% | -21.1% |
Q3 2019 | $1,356,000 | – | 15,499 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |